Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CCA, FVT

China Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial Results


BEIJING, Feb. 23, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its fourth quarter and fiscal year of 2017 financial results on Wednesday, February 28, 2018 after the market closes.

The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, March 1, 2018, which is 8:30 p.m., Beijing Time on March 1, 2018, to discuss fourth quarter and fiscal year of 2017 results. Listeners may access the call by dialing:

US:

1 888 346 8982

International:

1 412 902 4272

Hong Kong:

800 905 945

China:

400 120 1203

A telephone replay will be available one hour after the conclusion of the conference call through March 8, 2018. The dial-in details are:

US:

1 877 344 7529

International:

1 412 317 0088

Passcode:

10117579

A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.

About China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.

Contact:

China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: [email protected]

ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: [email protected]

SOURCE China Biologic Products Holdings, Inc.


These press releases may also interest you

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 18:57
Tribe Property Technologies Inc. (the "Issuer" or the "Company") , a leading provider of technology-elevated property management solutions, today announced that it expects to complete and file its 2023 Annual Filings (as defined below) on or before...

at 18:47
The Korean Cultural Center New York (KCCNY), a branch of the Ministry of Culture, Sports and Tourism of the Republic of Korea, is proud to present a special exhibition "Whanki in New York," from May 2 to June 13, 2024. This exhibition commemorates...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: